GLP-1s Next Act
Using two independent bioinformatic tools 29,30 , we found a significant overlap with transcripts associated with genetic susceptibility to obesity in humans, suggesting that GLP-1MK-801 targets biological pathways implicated in common polygenic forms of human obesity 1,31 (Fig
5.1 GLP1 Agonists Consistent findings of an increased risk of PD in individuals with type 2 diabetes [178] and risk reduction in those treated with certain antidiabetic drug classes including dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists [179,180,181] have moved insulin signaling into the focus of PD research as a target for disease-modifying intervention
Demers, A., McNicoll, N., Febbraio, M., Servant, M., Marleau, S., Silverstein, R., & Ong, H
You will not notice this
Trapp S, Richards JE